AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01483963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder exercises
Description: Home shoulder exercises, minimum of 3 times per day
Study NCT01483963 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Shoulder exercises
Description: Home shoulder exercises, minimum of 3 times per day
Study NCT01939600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amioca
Description: Starch-free breakfast plus 56.4g amioca starch
Study NCT03741218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freeze-dried grape (GRAP)/Placebo (PLA)
Description: The subjects will receive, after overnight fasting, either a monodose of freeze-dried grapes (equivalent to 300 g of fresh grapes) or isocaloric placebo solved in water, together with a high-fat breakfast. Blood samples will be collected before the intake, up to 5 h after breakfast, then a medium-fat lunch will be provided and blood samples will be collected for three additional hours. A total of 10 samples will be collected: 0-30-60-120-180-240-300-330-360-420 min. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
Study NCT03216005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BlueLeaf System
Description: The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.
Study NCT03860402 — intervention group
Intervention type: OTHER
Intervention: Temperature
Description: temperature of drug
Study NCT02467062 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: MRI measurement to evualuate for 4D blood flow pattern
Study NCT02467062 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI measurement to evualuate for 4D blood flow pattern
Study NCT00181285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Chest Wall Oscillator
Description: High velocity, low amplitude oscillatory airflow applied through a pneumatic vest worn over the thorax
Study NCT00181285 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High Frequency Chest Wall Oscillator
Description: High velocity, low amplitude oscillatory airflow applied through a pneumatic vest worn over the thorax
Study NCT02686463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Description: Laparoscopy is an operation performed in the abdomen or pelvis through small incisions (usually 0.5-1.5 cm) with the aid of a camera. It can either be used to inspect and diagnose a condition or to perform surgery.
Study NCT03083600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based Protein Hydrolysate 1
Description: Plant-based Protein Hydrolysate 2 for 12-weeks
Study NCT03083600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based Protein Hydrolysate 2
Description: Plant-based Protein Hydrolysate 2 for 12-weeks
Study NCT03083600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose Placebo for 12-weeks
Study NCT05697393 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shaker Pressure Band
Study NCT01669629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: delefilcon A
Description: Daily wear soft contact lens for bilateral distance vision correction use.
Study NCT02686463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparotomy
Description: A laparotomy is a surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity. It is also known as a celiotomy.
Study NCT01669629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: Daily wear soft contact lens for bilateral distance vision correction use.
Study NCT02324439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega Nutrition cold-milled flaxseeds
Description: Patients who are currently in clinical remission will receive a daily 20g dose of cold milled flaxseed as a dietary supplement to determine if this intervention prolongs clinical remission.
Study NCT02223026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin/metformin FDC
Study NCT02223026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/metformin FDC
Study NCT02223026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat, high caloric meal
Study NCT02960815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intanza
Study NCT02960815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mutagrip
Study NCT02960815 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mutagrip
Study NCT02960815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldara
Study NCT00698022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: risperidone daily for 28 days
Study NCT00698022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone
Description: risperidone daily for 28 days
Study NCT00698022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: mifepristone daily for 28 days
Study NCT00698022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mifepristone
Description: mifepristone daily for 28 days
Study NCT00698022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone-matched placebo
Description: risperidone-matched placebo daily for 28 days
Study NCT00698022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mifepristone-matched placebo
Description: mifepristone-matched placebo daily for 28 days
Study NCT03218735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Labor induction at 37.0 weeks to 37.6 weeks of gestation
Description: Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
Study NCT03218735 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Expectant monitoring and delivery
Description: Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
Study NCT04093180 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive Neurophysiological Rehabilitation System
Description: Intensive Neurophysiological Rehabilitation System (INRS) is a multicomponent approach that consists of different treatment modalities.
Study NCT04093180 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Activity and care as usual
Description: Control group continues usual activity and care while staying in the waiting list.
Study NCT02350530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI + Bevacizumab
Description: Bevacizumab 5mg/kg + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Study NCT02350530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOXIRI
Description: Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Study NCT03954561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopist-administered abdominal compression
Description: The endoscopist administers abdominal compression when loop formation encountered.
Study NCT03954561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: assistant-administered abdominal compression
Description: A assistant administers abdominal compression when loop formation encountered.
Study NCT03052166 — intervention group
Intervention type: DEVICE
Intervention: QT Ultrasound scan
Description: QT Ultrasound scan
Study NCT00439608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab,Paclitaxel, Carboplatin
Description: IV treatment for 6 weeks
Study NCT00887003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Low Volume, Low Dose (5cc, 5mg plain Bupivacaine)
Study NCT00887003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Low Volume, High Dose (5cc, 10mg plain Bupivacaine)
Study NCT05697393 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Shaker Pressure Band
Study NCT01440699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic human adipose-derived stem cells
Description: ALLO-ASC 1xE7 cells/mL is injected once along the fistula. If there is no safety issue for 4 weeks, 3 more people could be enrolled who are subject to ALLO-ASC 3xE7 cells/mL.
Study NCT02530307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-3951
Study NCT02530307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02969889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: video laryngoscope with a channel
Study NCT02969889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ILMA
Study NCT00682487 — intervention group
Intervention type: OTHER
Intervention: Hair sampling for cortisol
Description: Hair sampling for cortisol
Study NCT00887003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: High Volume, Low Dose (10cc, 5mg plain Bupivacaine)
Study NCT00887003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: High Volume, High Dose (10cc, 10mg plain Bupivacaine)
Study NCT00887003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Medrol
Description: 80mg Depo-Medrol
Study NCT02557945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Subjects will be treated with 400mg pills of gabapentin , titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
Study NCT02557945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
Study NCT01891591 — intervention group
Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass (RYGP)
Study NCT03952832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO
Study NCT03952832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03952832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02627014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: 6 treatments: 2 treatments for week~1 treatment = 30 minutes
Study NCT04243317 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle & diet
Description: The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans.
Study NCT04243317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle, diet & sleep
Description: The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans. The experimental group will additionally receive a sleep improvement program based on CBTi.
Study NCT04024618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition/Enteral Nutrition
Description: Patients randomized to the parenteral nutrition arm will receive nutrition by IV and patients randomized to the enteral nutrition arm will receive nutrition by NG tube.
Study NCT04024618 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Nutrition/Enteral Nutrition
Description: Patients randomized to the parenteral nutrition arm will receive nutrition by IV and patients randomized to the enteral nutrition arm will receive nutrition by NG tube.
Study NCT02238262 — intervention group
Intervention type: DRUG
Intervention: Telmisartan
Study NCT01854099 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEP-CMV
Description: 500 µg of PEP-CMV vaccine given intradermally on day 6-8 of each monthly TMZ cycle (standard 200 mg/m\^2 x 5 days) with group 1.
Study NCT01854099 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEP-CMV
Description: 500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (standard 200 mg/m\^2 x 5 days) with group 2.
Study NCT01854099 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEP-CMV
Description: 500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (dose-intensified 100 mg/m\^2 x 21 days) with group 3.
Study NCT00594854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400 (VIMOVO)
Description: PN400 tablet (500 mg delayed-release naproxen/20 mg immediate-release esomeprazole) given by mouth twice daily (bid).
Study NCT00594854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac/Misoprostol
Description: Over-encapsulated ARTHROTEC® 75 (75 mg diclofenac sodium/200 mcg misoprostol) capsules given by mouth bid.
Study NCT04160546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 MG
Description: Patients will receive ponatinib 15 mg/day for 104 weeks orally. Ponatinib will be self-administered by the patient on a daily schedule.~Acetyl salicylic acid (ASA) (100 mg) will be used such auxiliary medicinal product in order to prevent vascular occlusive events related with ponatinib.
Study NCT04160546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 100 MG
Description: Patients will receive acetylsalicylic acid 100 mg/day for 104 weeks orally.
Study NCT03506958 — intervention group
Intervention type: PROCEDURE
Intervention: Standard trauma care
Description: In both groups, all procedures and management will be done according to the hospital's standard of care.
Study NCT03996473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY 88-8223)
Description: 55 kBq/kg, intravenous (IV) injection, every 6 weeks for up to 6 administrations
Study NCT03996473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations
Study NCT03996473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations
Study NCT02212704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular stimulation by use of the turntable (static roll-tilt while the head is roll-tilted relative to the trunk)
Study NCT02212704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D-video-head impulse testing
Description: Evaluation of semicircular canal function. This intervention is part of the screening to determine suitability for this study
Study NCT02212704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular-evoked myogenic potentials (VEMPs)
Description: Evaluation of otolith function. This intervention is part of the screening to determine suitability for this study
Study NCT03712891 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Patients will receive coffee in a Styrofoam cup at a temperature of 125 degree Fahrenheit or less. Coffee will be offered to the patient in the PACU once the patient's gag reflex has been restored following their procedure. Volume of estimated coffee consumption will be measured using a sample scale (with a maximum of 300mL of coffee offered)
Study NCT05784584 — intervention group
Intervention type: PROCEDURE
Intervention: Blood samples collection
Description: The study population will take blood samples for virological and immunological measurements.
Study NCT03241745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg IV once every 4 weeks
Study NCT01381692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Given IV or SC
Study NCT01381692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV or SC
Study NCT01381692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO
Study NCT01381692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT01381692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01381692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01381692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01381692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01381692 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV
Study NCT01381692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT01381692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT04118660 — intervention group
Intervention type: OTHER
Intervention: Tissue Banking
Description: Blood, tissue, and fluid collection
Study NCT03364803 — intervention group
Intervention type: OTHER
Intervention: Cushing's QoL (Quality of Life Questionnaire)
Description: Cushing's QoL is a validated disease specific questionnaire consisting of 12 questions on a five-point Likert scale ranging from always to never. The total score ranges from 12 to 60, with a lower score indicating a greater negative impact on health related QoL. This is converted to a 0-100 scale, 0 indicating the worst and 100 indicating the best QoL
Study NCT03364803 — intervention group
Intervention type: OTHER
Intervention: Nottingham Health Profile (NHP)
Description: NHP is used in patients to assess general health and quality of life. This assessment consists of 38 yes/no questions that are subdivided into six scales assessing impairments: pain (eight items), energy level (three items), sleep (five items), emotional reactions (nine items), social isolation (five items) and physical mobility (eight items). A higher score indicates more impairment
Study NCT03364803 — intervention group
Intervention type: OTHER
Intervention: Hospital Anxiety and Depression Scale (HADS)
Description: HADS consists of 14 items pertaining to anxiety and depression, with each item measured on a four-point scale. Total scores for the anxiety and depression subscales range from 0 to 21. A higher score indicates greater symptomatology
Study NCT03364803 — intervention group
Intervention type: OTHER
Intervention: Perceived Stress Scale (PSS)
Description: The PSS predicts both objective biological markers of stress and increased risk of disease in patients with higher stress levels.
Study NCT03364803 — intervention group
Intervention type: OTHER
Intervention: Barratt's Impulsivity Scale (BIS)
Description: BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
Study NCT03364803 — intervention group
Intervention type: OTHER
Intervention: Beck Depression Inventory (BDI)
Description: BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
Study NCT00073788 — intervention group
Intervention type: PROCEDURE
Intervention: PET Scans
Description: PET Scan to look for coronary flow reserve, heart rate variability, and carotid ultrasound measures (mean intermediate thickness of the far fall of the carotid artery).
Study NCT00249847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled-release
Description: 2-12.5 mg tablets, orally, every day for 4 weeks
Study NCT00249847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen
Description: 0.625 mg tablet, orally, every day for 4 weeks
Study NCT04288778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)
Description: Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration. The study Treatment duration will be of 24 weeks.
Study NCT02269033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigated Latinas
Description: Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
Study NCT01698892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V Sedation
Description: Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation group
Study NCT01698892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual sedation
Description: Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
Study NCT00877487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate)
Description: 1 capsule (either 30, 50, or 70mg strength) per day for 6 weeks.